AstraZeneca (LON:AZN) has been assigned a GBX 6,500 ($87.21) price target by equities researchers at Barclays in a research report issued to clients and investors on Tuesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Barclays’ price objective would suggest a potential upside of 19.18% from the stock’s previous close.
A number of other equities analysts have also weighed in on AZN. Shore Capital reiterated a “hold” rating on shares of AstraZeneca in a research report on Friday, May 18th. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a GBX 5,500 ($73.80) price objective on shares of AstraZeneca in a research report on Tuesday, May 15th. UBS set a GBX 4,550 ($61.05) price objective on shares of AstraZeneca and gave the company a “neutral” rating in a research report on Friday, May 18th. Berenberg Bank reiterated a “buy” rating and issued a GBX 6,000 ($80.50) price objective on shares of AstraZeneca in a research report on Friday, May 18th. Finally, Deutsche Bank reiterated a “buy” rating on shares of AstraZeneca in a research report on Monday. Four research analysts have rated the stock with a sell rating, six have assigned a hold rating and fourteen have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of GBX 5,262.13 ($70.60).
AstraZeneca opened at GBX 5,454 ($73.18) on Tuesday, MarketBeat reports. AstraZeneca has a 1-year low of GBX 4,260 ($57.16) and a 1-year high of GBX 5,520 ($74.06).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.